You just read:

First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain

News provided by

Nektar Therapeutics

Jan 14, 2014, 08:00 ET